OKUR Stock Forecast & Price Target

OnKure Therapeutics is well positioned because its next-gen PI3Kα strategy is designed to selectively inhibit mutant PI3Kα while sparing wild-type signaling, a profile that could reduce off-target toxicity and widen the therapeutic index versus prior approaches. The company’s lead programs, OKI-345 and OKI-355, continue advancing toward clinical evaluation with IND submissions anticipated in 1H27, and preclinical data suggest stronger cellular selectivity across key PI3Kα mutations such as H1047R, E545K, and E542K, supporting best-in-class potential. Fundamentally, its $176M cash balance at 2Q, which should fund operations into 2029, provides a long runway to develop a differentiated pipeline in breast cancer and vascular anomalies while the expanding competitive landscape validates the commercial opportunity.

OnKure Therapeutics is viewed negatively because its valuation rests on a low 15% probability of approval for OKI-345, signaling substantial uncertainty around the lead asset’s clinical and commercial potential. The investment case is further weakened by meaningful execution and regulatory risk, including possible negative clinical results, delays in advancing candidates into registrational programs, and the chance of not obtaining approvals in a timely manner or at all. Competitive pressure from other mutant-selective PI3Kα inhibitors and long-term dilution risk also threaten shareholder value, especially for a clinical-stage company concentrated in one operating segment.